An interventional study of Complete Decongestive Therapy and Extracorporeal Shock Wave Therapy in Breast Cancer Related Lymphedema, sponsored by Ankara City Hospital Bilkent. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Ankara City Hospital Bilkent · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Breast Cancer Lymphedema with a site in Turkey — 5 open to participants now, 7 under way, none of them phase 3. Breast Cancer Lymphedema · Turkey.
Among the 34 studies in Breast Cancer Lymphedema with a site in Turkey, this one is the 4th largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2024, is one of 22 with no phase, and was the 33rd registered.
124 studies on the registry are indexed under Breast Cancer Lymphedema; 39 are open to participants now.
Browse Breast Cancer Lymphedema studies →5 of the 34 studies in Breast Cancer Lymphedema with a site in Turkey are open now. Recruiting first, the newest first:
Antalya City Hospital · Sites in Turkey
Ages 18–80 · Women only
Pamukkale University · Sites in Turkey
Ages 18–65 · Women only
Abant Izzet Baysal University · Sites in Turkey
Ages 18–85 · Women only
Hacettepe University · Sites in Turkey
Ages 40–65 · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 24 Breast Cancer Lymphedema studies recruiting now, 8 (33%) set no upper age limit and 9 (38%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is close to the median of 48 across 97 interventional studies indexed under Breast Cancer Lymphedema.
Median enrollment 40 across the 22 interventional studies, 56 across the 12 observational. Of the 23 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 34 has an industry lead sponsor. The 10 most frequent:
Ankara City Hospital Bilkent is the lead sponsor of 450 studies on the registry; 110 are open to participants now.
Ankara City Hospital Bilkent has 2 studies filed under Breast Cancer Lymphedema — fewer than ten, so there is no comparison to draw.
4 of the studies in Breast Cancer Lymphedema with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07154043Pamukkale UniversityComparison of IPC Therapy as an Alternative or an Adjunct to MLD Within CDT for BCRL | 2026-12-01 |
| NCT06697158Abant Izzet Baysal UniversityInvestigation of the Effects of Complex Decongestive Physiotherapy on Sleep Quality and Quality of Life in Women With Breast Cancer Related Lymphedema | 2026-12-12 |
| NCT07673939Hacettepe UniversityEffects of Core-Focused Exercise Training and Kinesiology Taping in Women With Breast Cancer-Related Lymphedema | 2027-08-15 |
| NCT07780240Antalya City HospitalAxillary Web Syndrome After Breast Cancer Surgery: Incidence, Risk Factors, and Functional Outcomes | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in Breast Cancer Lymphedema with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the effectiveness of extracorporeal shock wave therapy (ESWT) combined with complete decongestive therapy (CDT) compared with CDT alone in patients with breast cancer-related lymphedema.
Female patients with unilateral Stage II upper-extremity lymphedema related to breast cancer will be included. Participants will receive either complete decongestive therapy alone or complete decongestive therapy combined with extracorporeal shock wave therapy.
Clinical outcomes will be evaluated before treatment, immediately after treatment, and at 1 and 3 months after treatment. Primary outcomes will include limb circumference difference, volumetric measurements, and ultrasonographic assessment of skin and subcutaneous tissue thickness. Secondary outcomes will include upper-extremity function, quality of life, and pain.
Breast cancer-related lymphedema is a chronic condition characterized by impaired lymphatic drainage, accumulation of protein-rich interstitial fluid, chronic inflammation, and progressive tissue fibrosis. Complete decongestive therapy is currently considered the standard treatment for lymphedema. However, treatment response may be insufficient in some patients, and additional physical therapy modalities may be required.
Extracorporeal shock wave therapy is a mechanotherapy modality that generates high-amplitude mechanical acoustic waves. Previous studies suggest that low-energy ESWT may promote tissue regeneration, endothelial neoangiogenesis, modulation of inflammation, reduction of pain, prevention of soft-tissue fibrosis, and lymphangiogenesis.
The present study aims to investigate whether the addition of ESWT to complete decongestive therapy provides additional clinical benefits compared with complete decongestive therapy alone in patients with breast cancer-related Stage II lymphedema.
Unlike previous studies that have primarily evaluated short-term outcomes, participants in this study will also be assessed at 3 months after completion of treatment. In addition, only patients with a lymphedema duration of less than 4 years and Stage II disease will be included. Ultrasonographic assessment of skin and subcutaneous tissue thickness will also be performed to investigate the potential effects of ESWT on tissue fibrosis.
Inclusion Criteria:Female patients with unilateral upper-extremity lymphedema related to breast cancer.
At least 2 years have elapsed since the diagnosis of breast cancer, cancer treatment has been completed, and cure has been documented during oncology follow-up.
Stage II lymphedema according to the International Society of Lymphology classification.
Duration of lymphedema of less than 4 years.
Voluntary participation in the study. -
Exclusion Criteria: Poor general health status.
Open wounds, sensory deficits, or other conditions in the treatment area that may constitute a to treatment.
Active infection.
Presence of .
Bilateral breast cancer.
Bilateral lymphedema.
Use of anticoagulant therapy or presence of a coagulation disorder.
Cognitive impairment that may prevent completion of study assessment procedures.
Physical therapy, including electrotherapy or exercise therapy, ESWT, or regular use of nonsteroidal anti-inflammatory drugs within the previous 6 months.
Systemic inflammatory or disorders such as rheumatoid arthritis or systemic lupus erythematosus.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive Phase I complete decongestive therapy for three weeks. Treatment will consist of manual lymphatic drainage, multilayer short-stretch bandaging, and lymphedema exercises. Complete decongestive therapy will be administered five sessions per week for a total of 15 sessions.
Other: Complete Decongestive Therapy
Participants in this group will receive Phase I complete decongestive therapy together with extracorporeal shock wave therapy. Complete decongestive therapy will be administered five sessions per week for three weeks, for a total of 15 sessions. Extracorporeal shock wave therapy will be administered three sessions per week for three weeks.
Other: Complete Decongestive Therapy · Device: Extracorporeal Shock Wave Therapy
Complete decongestive therapy will consist of manual lymphatic drainage performed by an experienced physiotherapist according to the Vodder technique for 45-60 minutes, followed by multilayer short-stretch bandaging and lymphedema exercises performed under the supervision of the physiotherapist. Treatment will be administered five sessions per week for a total of 15 sessions. Arm Cross-Reference: Complete Decongestive Therapy Complete Decongestive Therapy Plus Extracorporeal Shock Wave Therapy
Also known as: CDT
Radial extracorporeal shock wave therapy will be administered using a pressure of 2 bar, a frequency of 4 Hz, and a total of 2,500 shocks per session. The shocks will be distributed as follows: Axillary region: 750 shocks Upper arm: 500 shocks Cubital region: 250 shocks Forearm: 500 shocks Dorsum of the hand: 500 shocks ESWT will be administered three sessions per week for three weeks. Arm Cross-Reference: Complete Decongestive Therapy Plus Extracorporeal Shock Wave Therapy
Also known as: ESWT
Change in Upper-Extremity Circumference Difference
Circumference measurements will be obtained from both the affected and unaffected upper extremities, and the difference between the two extremities will be recorded.
Time frame: Baseline, immediately after completion of the 3-week treatment, 1 month after treatment, and 3 months after treatment.
Change in Upper-Extremity Volume
Upper-extremity volume will be calculated from serial circumference measurements using the truncated cone formula.
Time frame: Baseline, immediately after completion of the 3-week treatment, 1 month after treatment, and 3 months after treatment.
Change in Skin and Subcutaneous Tissue Thickness Assessed by Ultrasonography
Skin and subcutaneous tissue thickness will be assessed ultrasonographically at the dorsum of the hand, forearm, and upper arm.
Time frame: Baseline, immediately after completion of the 3-week treatment, 1 month after treatment, and 3 months after treatment.
Change in Upper-Extremity Function Assessed by the QuickDASH
Upper-extremity functional status will be assessed using the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire.
Time frame: Baseline, immediately after completion of the 3-week treatment, 1 month after treatment, and 3 months after treatment.
Change in Lymphedema-Related Quality of Life Assessed by LYMQOL
Lymphedema-related quality of life will be assessed using the Lymphedema Quality of Life Questionnaire (LYMQOL).
Time frame: Baseline, immediately after completion of the 3-week treatment, 1 month after treatment, and 3 months after treatment.
Change in Upper-Extremity Pain Assessed by Visual Analog Scale
Upper-extremity pain experienced during the previous week will be evaluated using a Visual Analog Scale (VAS).
Time frame: Baseline, immediately after completion of the 3-week treatment, 1 month after treatment, and 3 months after treatment.
Plan to share: No — There is currently no plan to share individual participant data (IPD) with other researchers. The study protocol does not include an IPD-sharing plan.
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Oct 2026, 22 months after the start.
Of 66 non-industry interventional studies with no phase under Breast Cancer Lymphedema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 22 months is above that.
Counting every sponsor, half of 69 studies reached it within 18 months; a quarter within 10 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ankara City Hospital Bilkent →